Baker Brothers Advisors - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 170 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2014. The put-call ratio across all filers is 2.47 and the average weighting 0.1%.

Quarter-by-quarter ownership
Baker Brothers Advisors ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2014$84,550,000
+241.3%
256,375
-29.3%
1.08%
+208.0%
Q4 2013$24,775,000
-1.1%
362,8470.0%0.35%
-2.0%
Q3 2013$25,047,000
+20.7%
362,847
-21.6%
0.36%
-13.4%
Q2 2013$20,754,000462,8470.41%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q2 2014
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 640,688$9,514,0001.49%
CM Management, LLC 45,000$668,0000.50%
EULAV Asset Management 660,000$9,801,0000.26%
DLD Asset Management, LP 225,200$3,346,0000.24%
Virtus ETF Advisers LLC 21,387$318,0000.14%
GSA CAPITAL PARTNERS LLP 79,145$1,175,0000.12%
Hennion & Walsh Asset Management, Inc. 136,720$2,030,0000.11%
ALTRINSIC GLOBAL ADVISORS LLC 168,800$2,507,0000.08%
Inspire Investing, LLC 31,868$473,0000.06%
DUALITY ADVISERS, LP 51,196$760,0000.06%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders